Spero Therapeutics, Inc. (SPRO): R&D Expense
$38.47M
Year ended 2025-12-31
$20.53M
Trailing 12 months to 2026-06-30
-6.9%
3-year compound annual growth
-10.5%
5-year compound annual growth
+13.2%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $38.47M | -60.2% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $96.76M | +88.1% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $51.44M | +8.1% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $47.59M | -26.2% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $64.53M | -3.7% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $67.00M | +1.9% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $65.78M | +94.1% | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | $33.88M | +3.1% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $32.87M | +24.8% | 2019-03-14, From 2017-01-01 |
| 2016-12-31 | $26.33M | +136.7% | 2019-03-14, From 2016-01-01 |
| 2015-12-31 | $11.12M | n/a | 2018-04-02, From 2015-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $38.47M | -60.2% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $251.07M | +47.7% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $106.74M | -18.8% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $0 | -100.0% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $11.90M | -79.0% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $338.93M | +42.3% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $115.11M | +16.1% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $132.16M | -8.2% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $64.81M | +15.9% |
Compare SPRO, KURA, ENTA, RMTI side by side · Screen every company in Pharmaceutical Preparations ↗